Piramal Pharma Limited has informed the Exchange regarding 'Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information'.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma has notified the stock exchange about an amendment to its internal Code of Fair Disclosure, which governs how the company handles and shares Unpublished Price Sensitive Information (UPSI). This code is a mandatory policy required under SEBI's Prohibition of Insider Trading Regulations, 2015, and applies to how the company communicates material information to the public, analysts, and investors. The specific changes made in the amendment have not been disclosed in the filing. Such amendments are typically procedural and may involve updates to disclosure timelines, authorized spokespersons, or internal approval processes.
This is a routine regulatory compliance update with no direct material impact on the company's financials, operations, or shareholder value. Investors should view this as a housekeeping measure rather than a meaningful event.